The immune checkpoint ligand PD-l1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200

OncoImmunology

Volumn 6, Issue 1, 2017, Pages

  Noman, Muhammad Zaeem ^a,b   Janji, Bassam ^b   Abdou, Abderemane ^a   Hasmim, Meriem ^a   Terry, Stéphane ^a   Tan, Tuan Zea ^c   Mami Chouaib, Fathia ^a   Thiery, Jean Paul ^a,d,e   Chouaib, Salem ^a  

^a Faculty of Medicine University of Paris Sud   (France)

^b LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e UNIVERSITÉ PARIS DIDEROT   (France)

Author keywords

Breast cancer; Epithelial tomesenchymal transition; MiR 200 and immunotherapy; PD L1; SLUG (SNAI2); SNAI1; ZEB 1

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR ZEB1; TWIST RELATED PROTEIN 1;

ARTICLE; BREAST CANCER; CANCER RESISTANCE; CANCER SUSCEPTIBILITY; CONFOCAL MICROSCOPY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; CYTOTOXICITY ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOTHERAPY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL; UPREGULATION; WESTERN BLOTTING;

EID: 85021038369     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1263412     Document Type: Article

References (20)

1. Puisieux A, Brabletz T, Caramel J. Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol 2014; 16:488-94; PMID:24875735; http://dx.doi.org/10.1038/ncb2976
2. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139:871-90; PMID:19945376; http://dx.doi.org/10.1016/j.cell.2009.11.007
3. Sharma P, Allison JP. The future of immune checkpoint therapy. Science 2015; 348:56-61; PMID:25838373; http://dx.doi.org/10.1126/science.aaa8172
4. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. New Engl J Med 2012; 366:2455-65; PMID:22658128; http://dx.doi.org/10.1056/NEJMoa1200694
5. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. New Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690
6. Barsoum IB, Smallwood CA, Siemens DR, Graham CH. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res 2014; 74:665-74; PMID:24336068; http://dx.doi.org/10.1158/0008-5472.CAN-13-0992
7. Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, Bronte V, Chouaib S. PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med 2014; 211:781-90; PMID:24778419; http://dx.doi. org/10.1084/jem.20131916
8. Messai Y, Gad S, Noman MZ, Le Teuff G, Couve S, Janji B, Kammerer SF, Rioux-Leclerc N, Hasmim M, Ferlicot S et al. Renal cell carcinoma programmed Death-ligand 1, a new direct target of Hypoxia-inducible Factor-2 Alpha, is regulated by von Hippel-Lindau gene mutation status. Eur Urol 2015; PMID:26707870; http://dx.doi.org/10.1016/j. eururo.2015.11.029
9. Chen J, Jiang CC, Jin L, Zhang XD. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann Oncol 2016; 27:409-16; PMID:26681673; http://dx.doi.org/10.1093/annonc/mdv615
10. Akalay I, Janji B, Hasmim M, Noman MZ, Andre F, De Cremoux P, Bertheau P, Badoual C, Vielh P, Larsen AK et al. Epithelial-tomesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis. Cancer Res 2013; 73:2418-27; PMID:23436798; http://dx.doi.org/10.1158/0008- 5472.CAN-12-2432
11. Akalay I, Tan TZ, Kumar P, Janji B, Mami-Chouaib F, Charpy C, Vielh P, Larsen AK, Thiery JP, Sabbah M et al. Targeting WNT1- inducible signaling pathway protein 2 alters human breast cancer cell susceptibility to specific lysis through regulation of KLF-4 and miR-7 expression. Oncogene 2015; 34:2261-71; PMID:24931170; http://dx. doi.org/10.1038/onc.2014.151
12. Noman MZ, Janji B, Hu S, Wu JC, Martelli F, Bronte V, Chouaib S. Tumor-promoting effects of myeloid-derived suppressor cells are potentiated by hypoxia-induced expression of miR-210. Cancer Res 2015; 75:3771-87; PMID:26206559; http://dx.doi.org/10.1158/0008- 5472.CAN-15-0405
13. Noman MZ, Janji B, Kaminska B, Van Moer K, Pierson S, Przanowski P, Buart S, Berchem G, Romero P, Mami-Chouaib F et al. Blocking hypoxia-induced autophagy in tumors restores cytotoxic T-cell activity and promotes regression. Cancer Res 2011; 71:5976-86; PMID:21810913; http://dx.doi.org/10.1158/0008- 5472.CAN-11-1094
14. Noman MZ, Buart S, Romero P, Ketari S, Janji B, Mari B, Mami- Chouaib F, Chouaib S. Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells. Cancer Res 2012; 72:4629-41; PMID:22962263; http://dx.doi.org/10.1158/0008-5472. CAN-12-1383
15. Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, Zhang X, Yi X, Dwyer D, Lin W et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PDL1 expression and intratumoral immunosuppression. Nat Commun 2014; 5:5241; PMID:25348003; http://dx.doi.org/10.1038/ncomms6241
16. Mak MP, Tong P, Diao L, Cardnell RJ, Gibbons DL, William WN, Skoulidis F, Parra ER, Rodriguez-Canales J, Wistuba II et al. A patient-derived, pan-cancer EMT signature identifies global molecular alterations and immune target enrichment following epithelial-to-mesenchymal transition. Clin Cancer Res 2016; 22:609-20; PMID:26420858; http://dx.doi.org/10.1158/1078-0432. CCR-15-0876
17. Ou JN, Wiedeman AE, Stevens AM. TNF-alpha and TGF-beta counter-regulate PD-L1 expression on monocytes in systemic lupus erythematosus. Sci Rep 2012; 2:295; PMID:22389764; http://dx.doi. org/10.1038/srep00295
18. Starke A, Wuthrich RP, Waeckerle-Men Y. TGF-beta treatment modulates PD-L1 and CD40 expression in proximal renal tubular epithelial cells and enhances CD8 cytotoxic T-cell responses. Nephron Exp Nephrol 2007; 107:e22-9; PMID:17671397; http://dx.doi.org/10.1159/000106506
19. Ferrand N, Gnanapragasam A, Dorothee G, Redeuilh G, Larsen AK, Sabbah M. Loss of WISP2/CCN5 in estrogen-dependent MCF7 human breast cancer cells promotes a stem-like cell phenotype. PloS one 2014; 9:e87878; PMID:24498388; http://dx.doi.org/10.1371/journal.pone.0087878
20. Ye X, Tam WL, Shibue T, Kaygusuz Y, Reinhardt F, Ng Eaton E, Weinberg RA. Distinct EMT programs control normal mammary stem cells and tumour-initiating cells. Nature 2015; 525:256-60; PMID:26331542; http://dx.doi.org/10.1038/nature14897